Literature DB >> 29719037

Provider Variation in Antibiotic Prescribing and Outcomes of Respiratory Tract Infections.

Mahesh Manne1, Abhishek Deshpande1, Bo Hu1, Aditi Patel1, Glen B Taksler1, Anita D Misra-Hebert1, Stacey E Jolly1, Andrei Brateanu1, Robert W Bales1, Michael B Rothberg1.   

Abstract

OBJECTIVES: Inappropriate antibiotic use for respiratory tract infection (RTI) is an ongoing problem linked to the emergence of drug resistance and other adverse effects. Less is known about the prescribing practices of individual physicians or the impact of physician prescribing habits on patient outcomes. We studied the prescribing practices of providers for acute RTIs in an integrated health system, identified patient factors associated with receipt of an antibiotic and assessed the relation between providers' adjusted prescribing rates and a number of patient outcomes.
METHODS: This was a retrospective analysis of adults with an RTI visit to any primary care providers across the Cleveland Clinic Health System in 2011-2012. Patients with a history of chronic obstructive pulmonary disease or immunocompromised status were excluded. Logistic regression was used to examine patient factors associated with receipt of an antibiotic.
RESULTS: Of 31,416 patients with an RTI, 54.8% received an antibiotic. Patient factors associated with antibiotic prescribing included white race (odds ratio [OR] 1.35, P < 0.001), presence of fever (OR 1.66, P < 0.001), and a diagnosis of bronchitis (OR 10.98, P < 0.001) or sinusitis (OR 33.85, P < 0.001). Among 290 providers with ≥10 RTI visits, adjusted antibiotic prescribing rates ranged from 0% to 100% (mean 49%). Antibiotics were prescribed more often for sinusitis (OR 33.85, P < 0.001), bronchitis (OR 10.98, P < 0.001), or pharyngitis (OR 1.76, P < 0.001) compared with upper respiratory tract infection. Patients who were prescribed antibiotics at the index visit were more likely to return for RTI within 1 year (adjusted OR 1.26, P < 0.001). Emergency department visits for respiratory complications were rare and not associated with antibiotic receipt.
CONCLUSIONS: Antibiotic prescribing for RTI varies widely among physicians and cannot be explained by patient factors. Patients prescribed antibiotics for RTI were more likely to return for RTI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29719037     DOI: 10.14423/SMJ.0000000000000795

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  5 in total

1.  Coding Bias in Respiratory Tract Infections May Obscure Inappropriate Antibiotic Use.

Authors:  Kathryn A Martinez; Mark Rood; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

2.  Attitudes of High Versus Low Antibiotic Prescribers in the Management of Upper Respiratory Tract Infections: a Mixed Methods Study.

Authors:  Aditi Patel; Elizabeth R Pfoh; Anita D Misra Hebert; Alexander Chaitoff; Aryeh Shapiro; Niyati Gupta; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2019-10-19       Impact factor: 5.128

3.  Factors associated with antibiotic prescribing in patients with acute respiratory tract complaints in Malta: a 1-year repeated cross-sectional surveillance study.

Authors:  Erika A Saliba-Gustafsson; Alexandra Dunberger Hampton; Peter Zarb; Nicola Orsini; Michael A Borg; Cecilia Stålsby Lundborg
Journal:  BMJ Open       Date:  2019-12-18       Impact factor: 2.692

4.  Barriers and facilitators to prudent antibiotic prescribing for acute respiratory tract infections: A qualitative study with general practitioners in Malta.

Authors:  Erika A Saliba-Gustafsson; Anna Nyberg; Michael A Borg; Senia Rosales-Klintz; Cecilia Stålsby Lundborg
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

5.  Provider views on rapid diagnostic tests and antibiotic prescribing for respiratory tract infections: A mixed methods study.

Authors:  Shana A B Burrowes; Tamar F Barlam; Alexandra Skinner; Rebecca Berger; Pengsheng Ni; Mari-Lynn Drainoni
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.